Stock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results

Stock Track11-08

Shares of ADMA Biologics (NASDAQ: ADMA) soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.

The biopharmaceutical firm, focused on developing and manufacturing plasma-derived biologics, reported a remarkable net income of $35.9 million for the third quarter. Additionally, ADMA Biologics posted an adjusted EBITDA of $45.4 million and a robust gross margin of 50%.

These strong financial figures, particularly the significant revenue growth and profitability, were warmly received by investors, driving the stock's after-hours surge. ADMA Biologics' commitment to innovation and strategic focus on expanding its product portfolio appear to be paying off, as reflected in its Q3 performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155580951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155580951","market":"us","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results","media":"Stock Track","content":"<p>Shares of ADMA Biologics (NASDAQ: ADMA) soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.</p>\n\n<p>The biopharmaceutical firm, focused on developing and manufacturing plasma-derived biologics, reported a remarkable net income of $35.9 million for the third quarter. Additionally, ADMA Biologics posted an adjusted EBITDA of $45.4 million and a robust gross margin of 50%.</p>\n\n<p>These strong financial figures, particularly the significant revenue growth and profitability, were warmly received by investors, driving the stock's after-hours surge. ADMA Biologics' commitment to innovation and strategic focus on expanding its product portfolio appear to be paying off, as reflected in its Q3 performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 05:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ADMA Biologics (NASDAQ: ADMA) soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.\nThe biopharmaceutical...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1155580951","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155580951","pubTimestamp":1731015181,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ADMA Biologics  soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.The biopharmaceutical firm, focused on developing and manufacturing plasma-derived biologics, reported a remarkable net income of $35.9 million for the third quarter. Additionally, ADMA Biologics posted an adjusted EBITDA of $45.4 million and a robust gross margin of 50%.These strong financial figures, particularly the significant rev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"股票追踪ADMA Biologics因第三季度业绩强劲而盘后飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"Shares of ADMA Biologics (NASDAQ: ADMA) soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.\nThe biopharmaceutical firm, focused on developing and manufacturing plasma-derived biologics, reported a remarkable net income of $35.9 million for the third quarter. Additionally, ADMA Biologics posted an adjusted EBITDA of $45.4 million and a robust gross margin of 50%.\nThese strong financial figures, particularly the significant revenue growth and profitability, were warmly received by investors, driving the stock's after-hours surge. ADMA Biologics' commitment to innovation and strategic focus on expanding its product portfolio appear to be paying off, as reflected in its Q3 performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155580951"}